The potential of new drugs for weight loss

Key points
In the traditionally undermarket healthcare sector, GLP-1 drugs have generated significant interest among investors.

With over 40% of the U.S. population considered obese and over 70% overweight, the growing interest in GLP-1 is understandable. Although these treatments are expensive, the costs associated with obesity and related diseases are equally significant.

Looking ahead, the market for weight loss drugs is expected to continue to expand rapidly, driven by various factors that could facilitate greater access by patients.

In addition, the growing list of potential new medical applications for GLP-1 could further expand its market potential.